AbbVie announced positive Phase 1 results for ABBV-295, a long-acting amylin analog for obesity treatment, showing meaningful weight loss of up to 9.8% over 12-13 weeks with weekly, biweekly, and monthly dosing options. The drug demonstrated a half-life of about 11-12 days, supporting less frequent dosing, and was generally well tolerated with mostly mild gastrointestinal side effects. These findings support advancing ABBV-295 into Phase 2 trials, offering a new non-incretin approach to obesity management distinct from current GLP-1 therapies.
AbbVie shares show steady interest on Pluang, with 74% of recent orders being buys. The stock price is USD 263.67, up 0.16% as of Sep 30, 2026 16:51 WIB, reflecting ongoing investor engagement in the health sector.
AbbVie announced positive Phase 2 results for zumilokibart, a monoclonal antibody targeting IL-13, in adults with moderate-to-severe atopic dermatitis. All dose regimens met the primary endpoint with significant improvements in skin severity and itch...
AbbVie presented 60 abstracts at the 2026 European Academy of Dermatology and Venereology Congress, showcasing new data on its dermatology portfolio including approved drugs risankizumab (SKYRIZI) and upadacitinib (RINVOQ), as well as investigational...
AbbVie has formed a new collaboration with Valkai to enhance its artificial intelligence (AI) capabilities in clinical development. This partnership aims to improve efficiency in clinical research, accelerate insight generation, and reduce drug devel...
AbbVie announced FDA approval of JUVMO™ (tavapadon), the first selective D1/D5 receptor agonist for treating adults with Parkinson's disease. JUVMO offers a novel approach to motor symptom control, improving daily functioning and increasing 'on' time...
AbbVie and Johnson & Johnson are both strong dividend stocks trading near their 52-week highs, but they differ significantly in risk and growth. AbbVie shows faster revenue growth and a higher dividend yield, driven by its immunology drugs, but faces...
